Financial Lp Hrt Purchases 34,636 Shares of Onconetix (NASDAQ:ONCO) Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt acquired 34,636 shares of Onconetix stock in a transaction on Friday, April 17th. The shares were purchased at an average price of $0.73 per share, with a total value of $25,284.28. Following the completion of the purchase, the insider owned 177,821 shares in the company, valued at $129,809.33. This represents a 24.19% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, April 21st, Financial Lp Hrt sold 49,710 shares of Onconetix stock. The shares were sold at an average price of $0.69, for a total transaction of $34,299.90.
• On Thursday, April 16th, Financial Lp Hrt sold 53,867 shares of Onconetix stock. The shares were sold at an average price of $0.73, for a total transaction of $39,322.91.
• On Monday, April 20th, Financial Lp Hrt sold 94,462 shares of Onconetix stock. The shares were sold at an average price of $0.75, for a total transaction of $70,846.50.
• On Wednesday, April 15th, Financial Lp Hrt acquired 92,554 shares of Onconetix stock. The shares were purchased at an average price of $0.76 per share, with a total value of $70,341.04.
• On Tuesday, April 14th, Financial Lp Hrt acquired 74,350 shares of Onconetix stock. The shares were purchased at an average price of $0.77 per share, with a total value of $57,249.50.

Onconetix Stock Performance

NASDAQ:ONCO opened at $0.73 on Thursday. The firm has a market cap of $477,371.20, a P/E ratio of 0.00 and a beta of 3.63. Onconetix, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $74.29. The firm has a 50-day simple moving average of $2.45 and a two-hundred day simple moving average of $8.45.

Institutional Trading of Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned approximately 0.84% of Onconetix as of its most recent filing with the Securities and Exchange Commission. 23.89% of the stock is owned by institutional investors.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.